Amarantus Selected by People's Bank of China for A
Post# of 30028
Posted On: 11/13/2015 8:34:08 AM
Amarantus Selected by People's Bank of China for Anhui SME Cross-Border Investment and Trade Cooperation Conference
Download as PDF
NOVEMBER 13, 2015
SAN FRANCISCO, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced that the Company has been selected by the People's Bank of China (PBOC) and Anhui Province government to participate in the Anhui SME Cross-border Investment and Trade Cooperation Conference (CITCC) being held on December 9-10, 2015, in Hefei City Anhui Province, China.
During this time, Amarantus executives will participate in high-level meetings with key officials, investors and potential strategic partners from China, focusing on global expansion opportunities for the Company’s therapeutics pipeline, specifically its Engineered Skin Substitute (ESS) program as a treatment for severe burns, as well as applications for its proprietary Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF).
Hosted by the PBOC and Anhui Province government, the conference provides a prominent platform to connect SMEs from the world’s largest economies to build cross-border partnerships and explore the possibilities of future joint ventures. Over 800 high-profile participants from the public and private sectors, including government officials, CEOs and top executives, will gather to discuss current local market trends of their respective industry and spark strategic ideas on future development through exclusive information exchanges. The event also features a distinguished panel of prominent figures, speaking about important SME development related issues.
“In light of the recent tragedies in Shangdong and Tianjin where explosions killed and severely injured hundreds of people, there is a pressing need for a game-changing wound care product such as ESS in China where growth and expansion will undoubtedly be coupled with construction and manufacturing-related accidents that will likely continue to have a devastating impact,” said Gerald E. Commissiong, President & CEO of Amarantus.
About the Anhui SME Cross-border Investment and Trade Cooperation Conference
The Small and Medium-sized Enterprises (SME) Cross-border Investment and Trade Cooperation Conference (CITCC) provides a prominent stage for SMEs from the world’s largest economies to build cross-border partnerships by traveling to Hefei City where prospective partners meet and see for themselves the possibilities of a future joint venture. It echoes a measurable surge of Chinese investments outside of China in recent years, both in magnitude and diversity, and is also called for as cross-border dynamism between SMEs in and out of China is picking up steam. At the center of live interaction, SMEs will meet and establish long-lasting cooperation with potential Chinese partners, based on successful video pairing beforehand.
Download as PDF
NOVEMBER 13, 2015
SAN FRANCISCO, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced that the Company has been selected by the People's Bank of China (PBOC) and Anhui Province government to participate in the Anhui SME Cross-border Investment and Trade Cooperation Conference (CITCC) being held on December 9-10, 2015, in Hefei City Anhui Province, China.
During this time, Amarantus executives will participate in high-level meetings with key officials, investors and potential strategic partners from China, focusing on global expansion opportunities for the Company’s therapeutics pipeline, specifically its Engineered Skin Substitute (ESS) program as a treatment for severe burns, as well as applications for its proprietary Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF).
Hosted by the PBOC and Anhui Province government, the conference provides a prominent platform to connect SMEs from the world’s largest economies to build cross-border partnerships and explore the possibilities of future joint ventures. Over 800 high-profile participants from the public and private sectors, including government officials, CEOs and top executives, will gather to discuss current local market trends of their respective industry and spark strategic ideas on future development through exclusive information exchanges. The event also features a distinguished panel of prominent figures, speaking about important SME development related issues.
“In light of the recent tragedies in Shangdong and Tianjin where explosions killed and severely injured hundreds of people, there is a pressing need for a game-changing wound care product such as ESS in China where growth and expansion will undoubtedly be coupled with construction and manufacturing-related accidents that will likely continue to have a devastating impact,” said Gerald E. Commissiong, President & CEO of Amarantus.
About the Anhui SME Cross-border Investment and Trade Cooperation Conference
The Small and Medium-sized Enterprises (SME) Cross-border Investment and Trade Cooperation Conference (CITCC) provides a prominent stage for SMEs from the world’s largest economies to build cross-border partnerships by traveling to Hefei City where prospective partners meet and see for themselves the possibilities of a future joint venture. It echoes a measurable surge of Chinese investments outside of China in recent years, both in magnitude and diversity, and is also called for as cross-border dynamism between SMEs in and out of China is picking up steam. At the center of live interaction, SMEs will meet and establish long-lasting cooperation with potential Chinese partners, based on successful video pairing beforehand.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼